A Phase 1, Randomised, Open-Label, Three-way, Three-period, Crossover Relative Bioavailability Study to Assess the Single-Dose Pharmacokinetics of FOR-6219 in Capsule and Tablet Formulations in Postmenopausal Women
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs FOR-6219 (Primary) ; FOR-6219 (Primary)
- Indications Endometriosis
- Focus Pharmacokinetics
- Sponsors Forendo Pharma
- 28 Jan 2021 Status changed from active, no longer recruiting to completed.
- 14 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2021 New trial record